Hypoglycemic Effect

The hypoglycemic effect is the reduction of glucose concentration in the blood, a key outcome in maintaining metabolic balance and managing diabetes. In biochemical systems, it may result from increased insulin release or sensitivity, reduced glucose production by the liver, enhanced cellular glucose uptake, or slowed intestinal absorption. Researchers evaluate this effect using blood glucose measurements and related indicators such as insulin activity and glycogen metabolism. Understanding these mechanisms supports the study of hormones, enzymes, nutrients, and therapeutic compounds, while helping assess potential treatments for hyperglycemia and disorders of glucose regulation.

Hypoglycemic Effect - Related Videos

Education

JoVE Core - Pharmacology

Oral Hypoglycemic Agents: Glinides

0 Views •

2024

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

Oral Hypoglycemic Agents: Sulfonylureas

0 Views •

2024

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

Oral Hypoglycemic Agents: Biguanides and Glitazones

0 Views •

2024

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

Research

JoVE Journal - Medicine

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice

0 Views •

Cited by 4 •

2024

A hyperglycemic clamp is used for measuring insulin release with a maintained higher blood glucose concentration. A hypoglycemic clamp is for measuring glucose production induced by counter-regulatory responses. Both methods use the same surgical procedure. Here, we present a clamp technique to assess systemic glucose metabolism.

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

0 Views •

2024

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells. Acarbose and miglitol are typically...

View All Results

FAQs

Related Topics